AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACHV
  4. [Form 4] Achieve Life Sciences, Inc. Insider Trading Activity

[Form 4] Achieve Life Sciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Insider transactions by Cindy Jacobs at Achieve Life Sciences (ACHV) show settlement of performance restricted stock units into common stock and a small sale to cover tax withholding. On 09/04/2025 Ms. Jacobs had 110,000 shares acquired upon settlement of PRSUs and separately sold 27,629 shares at a weighted average price between $2.68 and $2.88 to satisfy income tax withholding obligations. Following these transactions she beneficially owned 115,585 shares of common stock. The filing states the PRSUs were previously reported as earned after Compensation Committee certification and that some PRSUs vest subject to milestone conditions, with certain awards exercisable or settling on specified future dates.

Operazioni insider di Cindy Jacobs in Achieve Life Sciences (ACHV): sono state convertite performance restricted stock unit in azioni ordinarie e effettuata una piccola vendita per coprire la ritenuta fiscale. In data 09/04/2025 la Sig.ra Jacobs ha acquisito 110.000 azioni a seguito della liquidazione delle PRSU e, separatamente, ha venduto 27.629 azioni a un prezzo medio ponderato compreso tra $2,68 e $2,88 per soddisfare obblighi di ritenuta fiscale sul reddito. Dopo queste operazioni deteneva beneficiariamente 115.585 azioni ordinarie. La comunicazione precisa che le PRSU erano gi脿 state segnalate come maturate dopo la certificazione del Compensation Committee e che alcune PRSU maturano al raggiungimento di specifici milestone, con taluni premi esercitabili o liquidabili in date future indicate.

Operaciones insider de Cindy Jacobs en Achieve Life Sciences (ACHV): se convirtieron unidades restringidas de acciones por desempe帽o en acciones ordinarias y se realiz贸 una peque帽a venta para cubrir la retenci贸n fiscal. El 09/04/2025 la Sra. Jacobs adquiri贸 110.000 acciones tras el vencimiento de las PRSU y, por separado, vendi贸 27.629 acciones a un precio medio ponderado entre $2,68 y $2,88 para satisfacer obligaciones de retenci贸n fiscal sobre la renta. Tras estas operaciones pose铆a beneficiariamente 115.585 acciones ordinarias. El informe indica que las PRSU ya se hab铆an comunicado como adquiridas tras la certificaci贸n del Compensation Committee y que algunas PRSU se consolidan al cumplirse hitos, con determinados premios ejercitables o liquidables en fechas futuras espec铆ficas.

Achieve Life Sciences(ACHV)鞚� Cindy Jacobs 雮措秬鞛� 瓯半灅: 靹标臣 鞝滍暅 欤检嫕雼渼(PRSUs)臧� 氤错喌欤茧 鞝曥偘霅橁碃 靹戈笀 鞗愳矞歆曥垬 於╇嫻鞚� 鞙勴暅 靻岆焿鞚� 毵る弰臧� 鞚措（鞏挫鞀惦媹雼�. 2025-09-04鞐� Jacobs 鞌姅 PRSU 鞝曥偘鞙茧 110,000欤茧ゼ 旆摑頄堨溂氅�, 氤勲弰搿� 靻岆摑靹� 鞗愳矞歆曥垬 鞚橂毳� 鞚错枆頃橁赴 鞙勴暣 臧�欷戫弶攴� 臧�瓴� $2.68鞐愳劀 $2.88 靷澊搿� 27,629欤茧ゼ 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅霌� 鞚错泟 攴鸽厐電� 氤错喌欤� 115,585欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 PRSU臧� 氤挫儊鞙勳洂須�(Compensation Committee) 鞚胳 頉� 鞚措 旆摑霅� 瓴冹溂搿� 氤搓碃霅橃棃瓿�, 鞚茧秬 PRSU電� 毵堨澕鞀ろ啢 臁瓣贝鞐� 霐半澕 氩犾姢韺呺悩氅� 韸轨爼 靾橃儊鞚� 歆�鞝曤悳 頄ロ泟 雮犾鞐� 頄夓偓霅橁卑雮� 鞝曥偘霅� 靾� 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.

Op茅rations d'initi茅 de Cindy Jacobs chez Achieve Life Sciences (ACHV) : des unit茅s d'actions restreintes li茅es 脿 la performance ont 茅t茅 converties en actions ordinaires et une petite vente a 茅t茅 r茅alis茅e pour couvrir la retenue fiscale. Le 04/09/2025 Mme Jacobs a acquis 110 000 actions suite au r猫glement des PRSU et a, s茅par茅ment, vendu 27 629 actions 脿 un prix moyen pond茅r茅 compris entre $2,68 et $2,88 afin de satisfaire aux obligations de retenue 脿 la source sur le revenu. 脌 la suite de ces op茅rations, elle d茅tenait b茅n茅ficiairement 115 585 actions ordinaires. Le d茅p么t indique que les PRSU avaient d茅j脿 茅t茅 signal茅es comme acquises apr猫s la certification du Compensation Committee et que certaines PRSU sont soumises 脿 des conditions d'茅tape, certaines attributions 茅tant exer莽ables ou r茅glables 脿 des dates futures sp茅cifi茅es.

Insider-Transaktionen von Cindy Jacobs bei Achieve Life Sciences (ACHV): Performance Restricted Stock Units wurden in Stammaktien umgewandelt und ein kleiner Verkauf zur Abdeckung der Steuerabz眉ge vorgenommen. Am 04.09.2025 erwarb Frau Jacobs infolge der Abwicklung der PRSUs 110.000 Aktien und verkaufte separat 27.629 Aktien zu einem gewichteten Durchschnittspreis zwischen $2,68 und $2,88, um Einkommenssteuerabz眉ge zu erf眉llen. Nach diesen Transaktionen hielt sie wirtschaftlich 115.585 Stammaktien. Die Meldung weist darauf hin, dass die PRSUs nach Zertifizierung durch das Compensation Committee bereits als verdient gemeldet wurden und dass einige PRSUs an Meilensteine gebunden sind, wobei bestimmte Zuwendungen an festgelegten zuk眉nftigen Terminen aus眉bbar oder abwickelbar sind.

Positive
  • 110,000 shares acquired upon settlement of performance restricted stock units, increasing insider alignment with shareholders
  • PRSU awards were certified by the Compensation Committee, indicating formal approval of performance achievement
  • Sale was explicitly for income tax withholding, showing the transaction was compensatory rather than discretionary trading
Negative
  • 27,629 shares were sold to satisfy tax obligations, reducing the newly settled shares retained
  • Some PRSUs have contingent vesting (0%鈥�100%) for certain awards, indicating future dilution is conditional and uncertain

Insights

TL;DR: Insider received a large equity compensation settlement and sold a modest portion to cover taxes; net ownership increased materially in absolute terms.

The filing documents settlement of PRSUs into 110,000 shares and a tax-related sale of 27,629 shares at a weighted average price range of $2.68鈥�$2.88. Net beneficial ownership after the transactions is 115,585 shares. These actions are compensation-driven rather than discretionary trading, as the sale is explicitly to satisfy tax withholding. For investors, this clarifies dilution from settled awards and the insiders current equity stake magnitude.

TL;DR: Compensation awards were certified and settled; transactions include customary tax withholding sales, consistent with standard executive equity practices.

The filing notes PRSUs were certified by the Compensation Committee and converted to shares. It discloses milestone-based vesting terms for some PRSUs and a net settlement process where the issuer sold shares to satisfy withholding. The use of net settlement and the attorney-in-fact signature on behalf of the reporting person are documented, aligning with routine governance and compliance procedures for equity compensation.

Operazioni insider di Cindy Jacobs in Achieve Life Sciences (ACHV): sono state convertite performance restricted stock unit in azioni ordinarie e effettuata una piccola vendita per coprire la ritenuta fiscale. In data 09/04/2025 la Sig.ra Jacobs ha acquisito 110.000 azioni a seguito della liquidazione delle PRSU e, separatamente, ha venduto 27.629 azioni a un prezzo medio ponderato compreso tra $2,68 e $2,88 per soddisfare obblighi di ritenuta fiscale sul reddito. Dopo queste operazioni deteneva beneficiariamente 115.585 azioni ordinarie. La comunicazione precisa che le PRSU erano gi脿 state segnalate come maturate dopo la certificazione del Compensation Committee e che alcune PRSU maturano al raggiungimento di specifici milestone, con taluni premi esercitabili o liquidabili in date future indicate.

Operaciones insider de Cindy Jacobs en Achieve Life Sciences (ACHV): se convirtieron unidades restringidas de acciones por desempe帽o en acciones ordinarias y se realiz贸 una peque帽a venta para cubrir la retenci贸n fiscal. El 09/04/2025 la Sra. Jacobs adquiri贸 110.000 acciones tras el vencimiento de las PRSU y, por separado, vendi贸 27.629 acciones a un precio medio ponderado entre $2,68 y $2,88 para satisfacer obligaciones de retenci贸n fiscal sobre la renta. Tras estas operaciones pose铆a beneficiariamente 115.585 acciones ordinarias. El informe indica que las PRSU ya se hab铆an comunicado como adquiridas tras la certificaci贸n del Compensation Committee y que algunas PRSU se consolidan al cumplirse hitos, con determinados premios ejercitables o liquidables en fechas futuras espec铆ficas.

Achieve Life Sciences(ACHV)鞚� Cindy Jacobs 雮措秬鞛� 瓯半灅: 靹标臣 鞝滍暅 欤检嫕雼渼(PRSUs)臧� 氤错喌欤茧 鞝曥偘霅橁碃 靹戈笀 鞗愳矞歆曥垬 於╇嫻鞚� 鞙勴暅 靻岆焿鞚� 毵る弰臧� 鞚措（鞏挫鞀惦媹雼�. 2025-09-04鞐� Jacobs 鞌姅 PRSU 鞝曥偘鞙茧 110,000欤茧ゼ 旆摑頄堨溂氅�, 氤勲弰搿� 靻岆摑靹� 鞗愳矞歆曥垬 鞚橂毳� 鞚错枆頃橁赴 鞙勴暣 臧�欷戫弶攴� 臧�瓴� $2.68鞐愳劀 $2.88 靷澊搿� 27,629欤茧ゼ 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅霌� 鞚错泟 攴鸽厐電� 氤错喌欤� 115,585欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 PRSU臧� 氤挫儊鞙勳洂須�(Compensation Committee) 鞚胳 頉� 鞚措 旆摑霅� 瓴冹溂搿� 氤搓碃霅橃棃瓿�, 鞚茧秬 PRSU電� 毵堨澕鞀ろ啢 臁瓣贝鞐� 霐半澕 氩犾姢韺呺悩氅� 韸轨爼 靾橃儊鞚� 歆�鞝曤悳 頄ロ泟 雮犾鞐� 頄夓偓霅橁卑雮� 鞝曥偘霅� 靾� 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.

Op茅rations d'initi茅 de Cindy Jacobs chez Achieve Life Sciences (ACHV) : des unit茅s d'actions restreintes li茅es 脿 la performance ont 茅t茅 converties en actions ordinaires et une petite vente a 茅t茅 r茅alis茅e pour couvrir la retenue fiscale. Le 04/09/2025 Mme Jacobs a acquis 110 000 actions suite au r猫glement des PRSU et a, s茅par茅ment, vendu 27 629 actions 脿 un prix moyen pond茅r茅 compris entre $2,68 et $2,88 afin de satisfaire aux obligations de retenue 脿 la source sur le revenu. 脌 la suite de ces op茅rations, elle d茅tenait b茅n茅ficiairement 115 585 actions ordinaires. Le d茅p么t indique que les PRSU avaient d茅j脿 茅t茅 signal茅es comme acquises apr猫s la certification du Compensation Committee et que certaines PRSU sont soumises 脿 des conditions d'茅tape, certaines attributions 茅tant exer莽ables ou r茅glables 脿 des dates futures sp茅cifi茅es.

Insider-Transaktionen von Cindy Jacobs bei Achieve Life Sciences (ACHV): Performance Restricted Stock Units wurden in Stammaktien umgewandelt und ein kleiner Verkauf zur Abdeckung der Steuerabz眉ge vorgenommen. Am 04.09.2025 erwarb Frau Jacobs infolge der Abwicklung der PRSUs 110.000 Aktien und verkaufte separat 27.629 Aktien zu einem gewichteten Durchschnittspreis zwischen $2,68 und $2,88, um Einkommenssteuerabz眉ge zu erf眉llen. Nach diesen Transaktionen hielt sie wirtschaftlich 115.585 Stammaktien. Die Meldung weist darauf hin, dass die PRSUs nach Zertifizierung durch das Compensation Committee bereits als verdient gemeldet wurden und dass einige PRSUs an Meilensteine gebunden sind, wobei bestimmte Zuwendungen an festgelegten zuk眉nftigen Terminen aus眉bbar oder abwickelbar sind.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JACOBS CINDY
(Last) (First) (Middle)
22722 29TH DR SE
SUITE 100
(Street)
BOTHELL WA 98021
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President & CMO
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/04/2025 M 110,000(1) A $0 143,214 D
Common Stock 09/04/2025 S 27,629(2) D $2.77(3) 115,585 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Restricted Stock Unit (PRSU)(4) (5) 09/04/2025 M 84,000 (6) 01/22/2028 Common Stock 84,000 $0 0 D
Performance Restricted Stock Unit (PRSU)(7) (5) 09/04/2025 M 26,000 (8) 01/28/2035 Common Stock 26,000 $0 104,000 D
Explanation of Responses:
1. Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II.
2. Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. Represents PRSUs previously reported on January 24, 2024 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors.
5. Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement.
6. Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones.
7. Represents PRSUs previously reported on January 30, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors.
8. Pursuant to the terms of the award agreement governing the PRSU, the number of underlying shares of the Issuer's common stock that may ultimately vest ranges from 0% to 100% of the number of the PRSUs initially granted, subject to certain milestones being met during the measurement period.
/s/ Sandra Thomson as attorney-in-fact for Cindy Jacobs 09/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did Cindy Jacobs report on ACHV Form 4?

The Form 4 reports the settlement of 110,000 PRSU shares into common stock and the sale of 27,629 shares to satisfy tax withholding.

How many ACHV shares does Cindy Jacobs beneficially own after the transactions?

Following the reported transactions, Cindy Jacobs beneficially owned 115,585 shares of ACHV common stock.

At what price were the withheld ACHV shares sold?

The withheld shares were sold at a weighted average price in the range of $2.68 to $2.88 per share.

Why were the ACHV shares sold by the issuer?

The issuer sold shares to satisfy income tax withholding and remittance obligations in connection with the net settlement of PRSUs.

Were the PRSU awards previously disclosed?

Yes, the PRSUs were previously reported on January 24, 2024 and January 30, 2025 as earned upon Compensation Committee certification.
Stock ACHV logo
Achieve Life Sciences Inc

NASDAQ:ACHV

ACHV Rankings

#4355 Ranked by Market Cap
N/A Ranked by Dividends

ACHV Latest News

Sep 11, 2025
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
Sep 3, 2025
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation
Sep 2, 2025
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Aug 7, 2025
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Jul 29, 2025
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

ACHV Latest SEC Filings

Sep 11, 2025
[8-K] Achieve Life Sciences, Inc. Reports Material Event
Sep 8, 2025
[Form 4] Achieve Life Sciences, Inc. Insider Trading Activity
Sep 8, 2025
[Form 4] Achieve Life Sciences, Inc. Insider Trading Activity
Sep 8, 2025
[Form 4] Achieve Life Sciences, Inc. Insider Trading Activity
Sep 8, 2025
[Form 4] Achieve Life Sciences, Inc. Insider Trading Activity

ACHV Stock Data

167.62M
49.28M
3.55%
61.41%
5.62%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
United States
SEATTLE